Molecular monitoring of chronic myelogenous leukemia: Identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts

Journal of Molecular Diagnostics

Volumn 8, Issue 2, 2006, Pages 231-239

  Wang, Y Lynn ^a   Lee, Joong Won ^a   Cesarman, Ethel ^a   Jin, David K ^a   Csernus, Balazs ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; BETA 2 MICROGLOBULIN; BETA ACTIN; BETA GLUCURONIDASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MESSENGER RNA; PHOSPHOGLYCERATE KINASE; TATA BINDING PROTEIN;

ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DEGRADATION KINETICS; FEMALE; GENE CONTROL; GENE IDENTIFICATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MALE; MEDICAL DECISION MAKING; QUANTITATIVE ANALYSIS; RNA DEGRADATION; TREATMENT RESPONSE;

EID: 33744535510     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2006.040404     Document Type: Article

References (31)

1. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science 1960, 132:1497-1499
2. Rowley JD: Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293
3. Hochhaus A, Weisser A, La Rosee P, Emig M, Muller MC, Saussele S, Reiter A, Kuhn C, Berger U, Hehlmann R, Cross NC: Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia 2000, 14:998-1005
4. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A, Cortes J: High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004, 103:2873-2878
5. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423-1432
6. Rosti G, Martinelli G, Bassi S, Amabile M, Trabacchi E, Giannini B, Cilloni D, Izzo B, De Vivo A, Testoni N, Cambrin GR, Bonifazi F, Soverini S, Luatti S, Gottardi E, Alberti D, Pane F, Salvatore F, Saglio G, Baccarani M: Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood 2004, 103:2264-2290
7. Mauro MJ, Druker BJ, Maziarz RT: Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 2004, 28(Suppl 1):S71-S73
8. Cortes J, O'Brien S, Kantarjian H: Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004, 104:2204-2205
9. Hochhaus A, La Rosee P: Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004, 18:1321-1331
10. Druker BJ: Overcoming resistance to imatinib by combining targeted agents. Mol Cancer Ther 2003, 2:225-226
11. Lee M, Khouri I, Champlin R, Kantarjian H, Talpaz M, Trujillo J, Freireich E, Deisseroth A, Stass S: Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation. Br J Haematol 1992, 82:708-714
12. Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC: Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 2000, 95:62-66
13. Paschka P, Muller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, Konig H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A: Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia 2003, 17:1687-1694
14. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NC, Hochhaus A: Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999, 13:1825-1832
15. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, Hehlmann R, Hiddemann W, Haferlach T: Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002, 16:53-59
16. Preudhomme C, Revillion F, Merlat A, Hornez L, Roumier C, Duflos-Grardel N, Jouet JP, Cosson A, Peyrat JP, Fenaux P: Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay. Leukemia 1999, 13:957-964
17. Branford S, Hughes TP, Rudzki Z: Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 1999, 107:587-599
18. Neumann F, Herold C, Hildebrandt B, Kobbe G, Aivado M, Rong A, Free M, Rossig R, Fenk R, Schneider P, Gattermann N, Royer-Pokora B, Haas R, Kronenwett R: Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation. Eur J Haematol 2003, 70:1-10
19. Jones CD, Yeung C, Zehnder JL: Comprehensive validation of a real-time quantitative bcr-abl assay for clinical laboratory use. Am J Clin Pathol 2003, 120:42-48
20. Eder M, Battmer K, Kafert S, Stucki A, Ganser A, Hertenstein B: Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation. Leukemia 1999, 13:1383-1389
21. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cave H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, Gonzalez M, Viehmann S, Malec M, Saglio G, van Dongen JJ: Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe Against Cancer program. Leukemia 2003, 17:2318-2357
22. Zanella I, Rossi G, Finazzi D, Capucci A, Albertini A, Cariani E: Quantification of bcr/abl mRNA expression by a rapid real-time reverse transcription-polymerase chain reaction assay in patients with chronic myeloid leukemia. Haematologica 2001, 86:318-319
23. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, Delabesse E, Macintyre E, Gottardi E, Saglio G, Watzinger F, Lion T, van Dongen JJ, Hokland P, Gabert J: Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR): a Europe against cancer program. Leukemia 2003, 17:2474-2486
24. Van Etten RA: c-Abl regulation: a tail of two lipids. Curr Biol 2003, 13:R608-R610
25. Hernandez SE, Krishnaswami M, Miller AL, Koleske AJ: How do Abl family kinases regulate cell shape and movement? Trends Cell Biol 2004, 14:36-44
26. Wange RL: TCR signaling: another Abl-bodied kinase joins the cascade. Curr Biol 2004, 14:R562-R564
27. Shaul Y, Ben-Yehoyada M: Role of c-Abl in the DNA damage stress response. Cell Res 2005, 15:33-35
28. Connor M, Ferguson-Smith M: Medical Genetics, ed 5. Oxford, Blackwell Science Ltd, 1997
29. Goetz CG: Textbook of Clinical Neurology, ed 2. St. Louis, MO, W.B. Saunders Company, 2003
30. Behrman RE, Kliegman RM, Jenson HB: Nelson Textbook of Pediatrics, ed 17. St. Louis, MO, W.B. Saunders Company, 2004
31. Lee JW, Chen Q, Knowles DM, Cesarman E, Wang YL: β-Glucoronidase is an optimal normalization control gene for molecular monitoring of chronic myelogenous leukemian. J Mol Diagn 2006, (in press)